CA1336073C - Traitement des tumeurs malignes a l'aide de 8-aminoadenosine - 3', 5' - phosphate cyclique et son mode de preparation - Google Patents

Traitement des tumeurs malignes a l'aide de 8-aminoadenosine - 3', 5' - phosphate cyclique et son mode de preparation

Info

Publication number: CA1336073C
Authority: CA; Canada
Prior art keywords: cyclic phosphate; day; tumor; aminoadenosine; chloroadenosine
Prior art date: 1987-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA000616661A

Other languages

English (en)

Inventor

Roland K. Robins

Ganapathi R. Revankar

Yu-An Chang

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

NUCLEIC ACID RESEARCH INSTITUTE AN ICN PHARMACEUTICALS Inc AND EASTMAN KODAK Co PARTNERSHIP

Original Assignee

NUCLEIC ACID RESEARCH INSTITUTE AN ICN PHARMACEUTICALS Inc AND EASTMAN KODAK Co PARTNERSHIP

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-21

Filing date

1993-06-16

Publication date

1995-06-27

1987-12-21 Priority claimed from US07/136,407 external-priority patent/US4861873A/en

1988-04-20 Priority claimed from CA000564584A external-priority patent/CA1326849C/fr

1993-06-16 Application filed by NUCLEIC ACID RESEARCH INSTITUTE AN ICN PHARMACEUTICALS Inc AND EASTMAN KODAK Co PARTNERSHIP filed Critical NUCLEIC ACID RESEARCH INSTITUTE AN ICN PHARMACEUTICALS Inc AND EASTMAN KODAK Co PARTNERSHIP

1993-06-16 Priority to CA000616661A priority Critical patent/CA1336073C/fr

1995-06-27 Application granted granted Critical

1995-06-27 Publication of CA1336073C publication Critical patent/CA1336073C/fr

2008-04-20 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

229910019142 PO4 Inorganic materials 0.000 title claims abstract description 126
239000010452 phosphate Substances 0.000 title claims abstract description 126
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title claims abstract description 122
DVGWFQILDUEEGX-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(6,8-diaminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound NC1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O DVGWFQILDUEEGX-UUOKFMHZSA-N 0.000 title claims abstract description 79
201000011510 cancer Diseases 0.000 title abstract description 9
238000002360 preparation method Methods 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims abstract description 42
241001465754 Metazoa Species 0.000 claims abstract description 32
206010028980 Neoplasm Diseases 0.000 claims description 152
238000001802 infusion Methods 0.000 claims description 33
239000000203 mixture Substances 0.000 claims description 26
238000002347 injection Methods 0.000 claims description 18
239000007924 injection Substances 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 11
230000000259 anti-tumor effect Effects 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 4
238000001727 in vivo Methods 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims 2
239000002552 dosage form Substances 0.000 claims 2
CLLFEJLEDNXZNR-UUOKFMHZSA-N (4ar,6r,7r,7as)-6-(6-amino-8-chloropurin-9-yl)-2-hydroxy-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1Cl CLLFEJLEDNXZNR-UUOKFMHZSA-N 0.000 abstract description 31
238000003786 synthesis reaction Methods 0.000 abstract description 9
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 abstract description 7
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 abstract description 7
229930024421 Adenine Natural products 0.000 abstract description 4
229960000643 adenine Drugs 0.000 abstract description 4
150000003838 adenosines Chemical class 0.000 abstract description 4
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract description 2
239000008280 blood Substances 0.000 abstract 1
210000004369 blood Anatomy 0.000 abstract 1
241000699670 Mus sp. Species 0.000 description 76
MHDPPLULTMGBSI-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(6-amino-8-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical class ClC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MHDPPLULTMGBSI-UUOKFMHZSA-N 0.000 description 61
238000012360 testing method Methods 0.000 description 37
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 35
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
230000000694 effects Effects 0.000 description 32
238000000034 method Methods 0.000 description 27
239000000243 solution Substances 0.000 description 23
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
206010009944 Colon cancer Diseases 0.000 description 20
239000002126 C01EB10 - Adenosine Substances 0.000 description 18
229960005305 adenosine Drugs 0.000 description 18
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 17
230000012010 growth Effects 0.000 description 16
230000002045 lasting effect Effects 0.000 description 16
229910001868 water Inorganic materials 0.000 description 16
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
238000005259 measurement Methods 0.000 description 14
210000000689 upper leg Anatomy 0.000 description 14
230000008859 change Effects 0.000 description 13
239000003814 drug Substances 0.000 description 12
239000012634 fragment Substances 0.000 description 12
230000008569 process Effects 0.000 description 12
239000002904 solvent Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 11
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 10
239000002253 acid Substances 0.000 description 10
229950006790 adenosine phosphate Drugs 0.000 description 10
208000026310 Breast neoplasm Diseases 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 9
239000002246 antineoplastic agent Substances 0.000 description 9
239000003937 drug carrier Substances 0.000 description 9
239000011734 sodium Substances 0.000 description 9
239000007787 solid Substances 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
206010058467 Lung neoplasm malignant Diseases 0.000 description 8
238000007912 intraperitoneal administration Methods 0.000 description 8
201000005296 lung carcinoma Diseases 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
231100000419 toxicity Toxicity 0.000 description 8
230000001988 toxicity Effects 0.000 description 8
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 7
-1 compound 8-chloroadenosine 3',5'-cyclic phosphate Chemical class 0.000 description 7
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000036541 health Effects 0.000 description 6
239000012071 phase Substances 0.000 description 6
230000002441 reversible effect Effects 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 5
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
229910000041 hydrogen chloride Inorganic materials 0.000 description 5
231100000518 lethal Toxicity 0.000 description 5
230000001665 lethal effect Effects 0.000 description 5
231100001269 lethally toxic Toxicity 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
238000005481 NMR spectroscopy Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000034994 death Effects 0.000 description 4
231100000517 death Toxicity 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000001613 neoplastic effect Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000006188 syrup Substances 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
ROPMUQKCJYNROP-UUOKFMHZSA-N 8-chloro-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1Cl ROPMUQKCJYNROP-UUOKFMHZSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
150000003863 ammonium salts Chemical class 0.000 description 3
230000003042 antagnostic effect Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
239000002243 precursor Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
159000000000 sodium salts Chemical class 0.000 description 3
239000000725 suspension Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
238000005160 1H NMR spectroscopy Methods 0.000 description 2
VJUPMOPLUQHMLE-UUOKFMHZSA-N 8-Bromoadenosine Chemical compound BrC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VJUPMOPLUQHMLE-UUOKFMHZSA-N 0.000 description 2
FBVALAOQISRDRY-UHFFFAOYSA-N 8-chloro-7h-purin-6-amine Chemical compound NC1=NC=NC2=C1NC(Cl)=N2 FBVALAOQISRDRY-UHFFFAOYSA-N 0.000 description 2
125000006414 CCl Chemical group ClC* 0.000 description 2
101100219382 Caenorhabditis elegans cah-2 gene Proteins 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
108091006374 cAMP receptor proteins Proteins 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
229940000425 combination drug Drugs 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
PWBJWDKDPAPGED-UHFFFAOYSA-N n'-chlorobutanediamide Chemical compound NC(=O)CCC(=O)NCl PWBJWDKDPAPGED-UHFFFAOYSA-N 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
238000012809 post-inoculation Methods 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
230000004614 tumor growth Effects 0.000 description 2
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
LNQVTSROQXJCDD-KQYNXXCUSA-N 3'-AMP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H]1O LNQVTSROQXJCDD-KQYNXXCUSA-N 0.000 description 1
FUGLSCLKXWRWTR-CRKDRTNXSA-N 9-[(2s,3r,4s,5r)-2-chloro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@@]1(Cl)N1C(NC=NC2=O)=C2N=C1 FUGLSCLKXWRWTR-CRKDRTNXSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
208000007093 Leukemia L1210 Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
208000006268 Sarcoma 180 Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
239000005708 Sodium hypochlorite Substances 0.000 description 1
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
DMKPWSUIRIENJW-UUOKFMHZSA-N [(2r,3s,4r,5r)-5-(6-amino-8-chloropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound ClC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O DMKPWSUIRIENJW-UUOKFMHZSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
RLGQACBPNDBWTB-UHFFFAOYSA-N cetyltrimethylammonium ion Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)C RLGQACBPNDBWTB-UHFFFAOYSA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
235000020426 cherry syrup Nutrition 0.000 description 1
238000010549 co-Evaporation Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229940126214 compound 3 Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
208000010749 gastric carcinoma Diseases 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
231100000682 maximum tolerated dose Toxicity 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000000155 melt Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
IOQPZZOEVPZRBK-UHFFFAOYSA-O octylazanium Chemical compound CCCCCCCC[NH3+] IOQPZZOEVPZRBK-UHFFFAOYSA-O 0.000 description 1
238000005457 optimization Methods 0.000 description 1
229940100691 oral capsule Drugs 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
230000000063 preceeding effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000005180 public health Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
208000025421 tumor of uterus Diseases 0.000 description 1
238000007039 two-step reaction Methods 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Landscapes

Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000616661A 1987-12-21 1993-06-16 Traitement des tumeurs malignes a l'aide de 8-aminoadenosine - 3', 5' - phosphate cyclique et son mode de preparation Expired - Fee Related CA1336073C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000616661A CA1336073C (fr)	1987-12-21	1993-06-16	Traitement des tumeurs malignes a l'aide de 8-aminoadenosine - 3', 5' - phosphate cyclique et son mode de preparation

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US136,407		1987-12-21
US07/136,407 US4861873A (en)	1987-12-21	1987-12-21	8-Chloroadenosine 3', 5'-cyclic monophosphate preparations
US18007088A	1988-04-11	1988-04-11
US180,070		1988-04-11
CA000564584A CA1326849C (fr)	1987-12-21	1988-04-20	Traitement de tumeurs malignes a l'aide de 8-chloroadenosine-3', 5'-cyclophosphate, et sa preparation
CA000616661A CA1336073C (fr)	1987-12-21	1993-06-16	Traitement des tumeurs malignes a l'aide de 8-aminoadenosine - 3', 5' - phosphate cyclique et son mode de preparation

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000564584A Division CA1326849C (fr)	1987-12-21	1988-04-20	Traitement de tumeurs malignes a l'aide de 8-chloroadenosine-3', 5'-cyclophosphate, et sa preparation

Publications (1)

Publication Number	Publication Date
CA1336073C true CA1336073C (fr)	1995-06-27

Family

ID=27167930

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000616661A Expired - Fee Related CA1336073C (fr)	1987-12-21	1993-06-16	Traitement des tumeurs malignes a l'aide de 8-aminoadenosine - 3', 5' - phosphate cyclique et son mode de preparation

Country Status (1)

Country	Link
CA (1)	CA1336073C (fr)

1993
- 1993-06-16 CA CA000616661A patent/CA1336073C/fr not_active Expired - Fee Related

Legal Events

Date	Code	Title	Description
2006-06-27	MKLA	Lapsed

Publication	Publication Date	Title
DE69822482T2 (de)	2005-03-03	Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
DE3882985T2 (de)	1994-03-03	Adenosin-deaminase-stabile anti-retroviral-nukleoside.
CA2111571C (fr)	2005-08-23	Nucleosides pyrimidine acyles utilises pour traiter la toxicite des agents chimiotherapeutiques et antiviraux
SK119993A3 (en)	1994-04-06	Antiviral combinations
Rosowsky et al.	1982	Lipophilic 5'-alkyl phosphate esters of 1-. beta.-D-arabinofuranosylcytosine and its N4-acyl and 2, 2'-anhydro-3'-O-acyl derivatives as potential prodrugs
JPH04505932A (ja)	1992-10-15	三つの新規非ポリグルタマートのデアザアミノプテリンと合成方法
US7091334B2 (en)	2006-08-15	Method for large-scale production of di(uridine 5′)-tetraphosphate and salts thereof
EP1100512A4 (fr)	2001-10-10	Elaboration de composes de thioarabinofuranosyl et leurs applications
US5036103A (en)	1991-07-30	Method of treating cancer cells in humans
CN115785107B (zh)	2024-11-12	一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途
EP0788495A2 (fr)	1997-08-13	Nucleosides l-erythrosyle
US4507301A (en)	1985-03-26	Anti-cancer composition for delivering 5-fluorouracil
US5041542A (en)	1991-08-20	Substituted pyrimido[5,4-d]pyrimidine nucleosides
US4861873A (en)	1989-08-29	8-Chloroadenosine 3', 5'-cyclic monophosphate preparations
CA1336073C (fr)	1995-06-27	Traitement des tumeurs malignes a l'aide de 8-aminoadenosine - 3', 5' - phosphate cyclique et son mode de preparation
WO1989005817A1 (fr)	1989-06-29	Purines antitumorales de 6-sulfenamide, 6-sulfinamide et 6-sulfonamide, nucleosides de purine, nucleotides de purine et composes apparentes
CA1326849C (fr)	1994-02-08	Traitement de tumeurs malignes a l'aide de 8-chloroadenosine-3', 5'-cyclophosphate, et sa preparation
CN100381459C (zh)	2008-04-16	阿霉素的衍生物及其制备方法和用途
IE902656A1 (en)	1991-02-27	Salts of n5,n10-methylene-5,6,7,8-tetrahydrofolic acid
US4925930A (en)	1990-05-15	Synthesis and anti-leukemic activity of alkyl-1-(β-D-ribofuranosyl)[1,2,4]triazole-3-carboximidates
US5885972A (en)	1999-03-23	L-pyranosyl nucleosides
MXPA97002927A (es)	1998-04-01	L-piranosilnucleosidos
US5026836A (en)	1991-06-25	6-sulfenamide, 6-sulfinamide and 6-sulfonamide purines, purine nucleosides, purine nucleotides, pharmaceutical compositions, and processes of making
JPH07233187A (ja)	1995-09-05	５−フルオロウリジン誘導体の製造および医薬組成物
EP1968971B1 (fr)	2013-03-27	Dérivés de dioxolanne pour le traitement du cancer